Trials / Completed
CompletedNCT00385255
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
A Study to Evaluate Immunogenicity and Safety of Boostrix When Co-administered With Fluarix in Subjects 19 Years of Age and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,726 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years. This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Fluarix® | GSK Biologicals' inactivated influenza split virus vaccine. |
| BIOLOGICAL | Boostrix® | GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum. |
Timeline
- Start date
- 2006-10-23
- Primary completion
- 2007-02-28
- Completion
- 2007-02-28
- First posted
- 2006-10-09
- Last updated
- 2019-06-10
- Results posted
- 2018-09-17
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00385255. Inclusion in this directory is not an endorsement.